BDRX Fair Value & Analysis
Healthcare · US · Market cap $2.2M
BDRX
BDRX · US
Fair value as of: Jul 14, 2026
From 1 valuation models · updated today
Share price −23.8% over the past month.
Price vs Fair Value (12 months)
12‑month range $2.31 – $54.50 · fair‑value band $2.55 – $4.82 · the $2.31 price screens below the $3.86 fair value. As of Jul 14, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
BDRX (BDRX) currently trades at $2.31, while our model-based Fair Value estimate is $3.86 — implying the stock looks roughly 67.1% undervalued today. We read business quality at 16/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Trailing-twelve-month revenue stands at $83.0K. Revenue declined 64.1% year over year. It earns a return on equity of -64.7%. The balance sheet holds a net cash position of $8.5M. Fundamentals as of Jul 14, 2026
Our scenario range runs from $2.55 (bear case) to $4.82 (bull case); at $2.31, the current price sits below that range. For context, the median of 10 Healthcare peers we cover trades at -27% fair-value upside — at 67%, BDRX screens cheaper than that median.
Key figures & financial health
Figures from reported company fundamentals (EODHD) · as of Jul 14, 2026. TTM = trailing twelve months.
About the company
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTX240, for the treatment of gastrointestinal stromal tumors. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, nanotechnology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours; and MidaCore, a gold nanoparticle used for …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
BDRX reported revenue of $0 in FY2025 versus $578K in FY2021. Reported net income was −$6.2M in FY2025.
Is BDRX fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 14, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$582.92 | R$95.50 | -84% |
| Regeneron Pharmaceuticals, Inc REGN34 | R$54.63 | R$46.79 | -14% |
| UCB SA UCB | €247.60 | €180.06 | -27% |
| argenx SE ARGNF | $935.38 | $382.64 | -59% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
| CSL Limited CSL | A$116.32 | A$126.60 | +9% |
| Celltrion, Inc 068270 | 167,300 KRW | 76,382 KRW | -54% |
| BioNTech SE B1NT34 | R$29.19 | R$21.38 | -27% |
| Moderna, Inc M1RN34 | R$11.81 | R$3.77 | -68% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is BDRX undervalued?
What is the fair value of BDRX?
What is the quality score of BDRX?
What is the revenue of BDRX?
What is the net profit margin of BDRX?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Unlock the full BDRX analysis — and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.